Laboratorio Reig Jofre, S.A. Stock price

Equities

RJF

ES0165359029

Pharmaceuticals

Delayed BME 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
2.49 EUR +0.40% Intraday chart for Laboratorio Reig Jofre, S.A. -1.19% +10.67%
Sales 2024 * 342M 368M Sales 2025 * 368M 396M Capitalization 196M 211M
Net income 2024 * 14M 15.08M Net income 2025 * 24M 25.86M EV / Sales 2024 * 0.7 x
Net Debt 2024 * 43M 46.33M Net Debt 2025 * 20M 21.55M EV / Sales 2025 * 0.59 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
7.78 x
Employees 1,331
Yield 2024 *
-
Yield 2025 *
-
Free-Float 19.99%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spain’s Reig Jofre Names New CFO MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Laboratorio Reig Jofre, S.A., Q4 2022 Earnings Call, Mar 07, 2023
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Why Europe's drug shortages may get worse RE
Reig Jofre JV Inks Deal with Indian Pharmaceutical to Commercialize Biosimilar Medicine MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Laboratorio Reig Jofre, S.A.(BME:RJF) dropped from S&P Global BMI Index CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Laboratorio Reig Jofre, S.A.’s Equity Buyback announced on July 18, 2019 has Expired. The company has repurchased 74,107 shares, representing 0.1% for €0.26 million. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news

Latest transcript on Laboratorio Reig Jofre, S.A.

1 day+0.40%
1 week-1.19%
Current month-1.19%
1 month+0.40%
3 months+11.16%
6 months+0.40%
Current year+10.67%
More quotes
1 week
2.46
Extreme 2.46
2.57
1 month
2.45
Extreme 2.45
2.61
Current year
2.21
Extreme 2.21
2.61
1 year
2.15
Extreme 2.15
2.88
3 years
2.02
Extreme 2.02
6.08
5 years
1.87
Extreme 1.87
6.40
10 years
1.87
Extreme 1.87
9.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 05-12-31
Chief Tech/Sci/R&D Officer - 02-12-31
Chief Operating Officer 52 02-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 05-12-31
Director/Board Member - 14-12-30
Director/Board Member - 14-12-30
More insiders
Date Price Change Volume
24-03-28 2.49 +0.40% 3,394
24-03-27 2.48 -0.80% 7,817
24-03-26 2.5 +0.40% 6,955
24-03-25 2.49 +1.22% 9,853
24-03-22 2.46 -2.38% 13,352

Delayed Quote BME, March 28, 2024 at 12:35 pm EDT

More quotes
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company's activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Laboratorio Reig Jofre, S.A. - BME